Dental Care Clinics in Torrington, CT Accepting Medicare
26 Dental Care Clinics found. Showing 21 - 26
 Litchfield Hills Family Dental Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 241 Kennedy Dr, Torrington, CT 06790 Phone: 860-496-0256 Fax: 860-496-0863 |
Drs.coutant, Sederqust & Nebor, Dentists,pc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 55 Peck Rd, Torrington, CT 06790 Phone: 860-482-8588 Fax: 860-482-7596 |
O.m.s. Associates, P.c. Dentist - Oral and Maxillofacial Pathology Medicare: Not Enrolled in Medicare Practice Location: 1 Torrington Plaza, Suite 103, Torrington, CT 06790 Phone: 860-482-5779 Fax: 860-496-2345 |
Kennedy Dental Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 333 Kennedy Dr, Suite-102, Torrington, CT 06790 Phone: 860-496-1200 Fax: 860-496-0625 |
Isadore B Temkin Dds Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 42 Water St, Torrington, CT 06790 Phone: 860-482-5573 |
Pediatric Dentistry Of Litchfield County, Llc Dentist - Pediatric Dentistry Medicare: Not Enrolled in Medicare Practice Location: 148 Migeon Ave, Torrington, CT 06790 Phone: 860-482-9578 |
News Archive
Beta blockers prevent negative effects of stress
Stressed people fall into habits and their behaviour is not goal-directed. That the neurotransmitter norepinephrine plays a decisive role here is now reported in the Journal of Neuroscience by scientists from Bochum led by Dr. Lars Schwabe (RUB Faculty of Psychology).
A*STAR IHPC and IDA join to develop world-class cloud computing-powered technological solutions to benefit local ICT companies
Cloud solutions to accelerate local ICT companies' adoption of technologies and overcome end-user challenges faced by the ICT industry
USFDA approves Sun Pharma's generic Flomax ANDA
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted approval for its Abbreviated New Drug Application to market a generic version of Flomax ®, tamsulosin capsules.
FDA ODAC votes in favor of Onyx's Kyprolis
Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) determined by a vote of 11-0 with 1 abstention that, in patients with relapsed and refractory multiple myeloma who have received at least two prior lines of therapy that included a proteasome inhibitor and an immunomodulatory agent (IMiD), the benefit-risk assessment is favorable for the use of Kyprolis.
Acelrx fourth quarter net loss increases to $6.4 million
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the fourth quarter and year ended December 31, 2011.
› Verified 7 days ago
- 1
- 2(current)